Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2021-05-11 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Information Financiere du Premier Trimestre 2021
Earnings Release Classification · 98% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces "INFORMATION FINANCIERE DU PREMIER TRIMESTRE 2021" (First Quarter 2021 Financial Information). It provides key financial highlights (revenue, cash position) and updates on clinical trials. This structure—a brief announcement summarizing key financial metrics for a specific interim period (Q1 2021)—is the definition of an Earnings Release (ER). It is not the comprehensive Interim/Quarterly Report (IR) itself, but the initial announcement of the results. The document length (11,294 chars) is substantial but the format is that of a summary press release, not a full regulatory filing like a 10-K or IR. Q1 2021
2021-05-11 French
Innate Pharma First Quarter 2021 Report
Earnings Release Classification · 95% confidence The document is a press release titled 'Innate Pharma First Quarter 2021 Report'. It provides a summary of financial highlights (revenue, cash position) and operational updates (clinical trial progress, pipeline highlights) for the three-month period ending March 31, 2021. While it contains financial data, it is structured as a corporate press release rather than a comprehensive statutory quarterly report. According to the filing definitions, an 'Earnings Release' (ER) is the initial announcement of quarterly financial results containing key highlights, which matches this document's content and structure. Q1 2021
2021-05-11 English
FORM 6-K
Regulatory Filings
2021-05-04 English
Innate Pharma Organise une Conférence Téléphonique et un Webcast pour son Information Financière du Premier Trimestre 2021
Report Publication Announcement Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its main subject is announcing a conference call and webcast scheduled for May 11, 2021, following the release of the company's financial results for the first quarter of 2021 ("chiffre d'affaires et de sa position de trésorerie pour les trois premiers mois de l'année 2021"). This structure—announcing the date/time/access details for a call related to period-specific financial results—is characteristic of an Earnings Release (ER) or a Report Publication Announcement (RPA). Since the document itself is the announcement *about* the upcoming release and conference call, and not the detailed financial report (like an IR or 10-K), it fits best as an Earnings Release (ER) which typically precedes or accompanies the full results presentation, or an RPA. Given that it explicitly mentions the upcoming release of Q1 2021 financial figures and provides details for the associated call, ER is the most precise fit, as ERs often include the announcement of the call details. If it were purely about the *publication* of a report without mentioning the call details, RPA would be stronger. Since it focuses on the call related to the results, ER is selected.
2021-05-04 French
Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update
Report Publication Announcement Classification · 86% confidence The document is titled "INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR 2021 FIRST QUARTER BUSINESS UPDATE". It explicitly details the date, time, and method (webcast/telephone) for participants to join a conference call to discuss the first quarter of 2021 business progress. This content perfectly matches the definition of a Call Transcript (CT) if it were the transcript itself, or an announcement leading up to one. Since the document is an announcement *about* an upcoming conference call, and not the transcript of the call itself, it is most closely related to the event that generates a Call Transcript (CT). However, looking at the provided definitions, there is no specific category for 'Conference Call Announcement'. The content is focused on providing access details for a call where financial updates will be discussed. If the call is an earnings call, the announcement often precedes an Earnings Release (ER) or is related to the discussion of the Interim Report (IR). Given the focus is purely on the logistics of the *call* itself, and not the release of the financial results (which are only mentioned as the topic of the call), the closest fit among the options that relates to a scheduled discussion event is Call Transcript (CT), assuming this announcement is intrinsically linked to the CT event. Alternatively, if this announcement is considered a general regulatory communication about an upcoming event, RNS might apply. However, the specific nature of announcing a 'conference call' strongly suggests a connection to CT. Since the document is an announcement *of* the call, and not the transcript, and there is no 'Conference Call Announcement' code, I must choose the best fit. Since the document is short and announces an event where financial updates will be discussed, it is often grouped with ER or CT. Given the explicit mention of the 'conference call' details, CT is the most specific fit for the *type* of event being announced, even if this specific document is the announcement rather than the transcript itself. If this were a short announcement stating the ER is attached, RPA would be used. Here, the focus is the call logistics. I will classify it as CT based on the subject matter, acknowledging it is the announcement, not the transcript.
2021-05-04 English
FORM 6-K
Regulatory Filings
2021-04-28 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.